The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
Open accessAbstract
BACKGROUND: Data from randomized trials are lacking on the benefits and risks of initiating antiretroviral therapy in patients with asymptomatic human immunodeficiency virus (HIV) infection who have a CD4+ count of more than 350 cells per cubic millimeter. METHODS: We randomly assigned HIV-positive adults who had a CD4+ count of more than 500 cells per cubic millimeter to start antiretroviral therapy immediately (immediate-initiation group) or to defer it until the CD4+ count decreased to 350 cells per cubic millimeter or until the development of the acquired immunodeficiency syndrome (AIDS) or another condition that dictated the use of antiretroviral therapy (deferred-initiation group). The primary composite end point was any serious AIDS-related event, serious non-AIDS-related event, or death from any cause. RESULTS: A total of 4685 patients were followed for a mean of 3.0 years. At study entry, the median HIV viral load was 12,759 copies per milliliter, and the median CD4+ count was 651 cells per cubic millimeter. On May 15, 2015, on the basis of an interim analysis, the data and safety monitoring board determined that the study question had been answered and recommended that patients in the deferred-initiation group be offered antiretroviral therapy. The primary end point occurred in 42 patients in the immediate-initiation group (1.8%; 0.60 events per 100 person-years), as compared with 96 patients in the deferred-initiation group (4.1%; 1.38 events per 100 person-years), for a hazard ratio of 0.43 (95% confidence interval [CI], 0.30 to 0.62; P<0.001). Hazard ratios for serious AIDS-related and serious non-AIDS-related events were 0.28 (95% CI, 0.15 to 0.50; P<0.001) and 0.61 (95% CI, 0.38 to 0.97; P=0.04), respectively. More than two thirds of the primary end points (68%) occurred in patients with a CD4+ count of more than 500 cells per cubic millimeter. The risks of a grade 4 event were similar in the two groups, as were the risks of unscheduled hospital admissions. CONCLUSIONS: The initiation of antiretroviral therapy in HIV-positive adults with a CD4+ count of more than 500 cells per cubic millimeter provided net benefits over starting such therapy in patients after the CD4+ count had declined to 350 cells per cubic millimeter. (Funded by the National Institute of Allergy and Infectious Diseases and others; START ClinicalTrials.gov number, NCT00867048.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Castro, K. G., Ward, J. W., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,349
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
CD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
(1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500040022009 · Cited by 958
Grinsztejn, B., Hosseinipour, M. C., Ribaudo, H. J., Swindells, S., Eron, J., Chen, Y. Q., Wang, L., Ou, S.-S., Anderson, M., McCauley, M., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70692-3 · Cited by 494
Günthard, H. F., Aberg, J. A., Eron, J. J., Hoy, J. F., Telenti, A., Benson, C. A., Burger, D. M., Cahn, P., Gallant, J. E., Glesby, M. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.8722 · Cited by 449
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2008) · The Journal of Infectious Diseases · doi:10.1086/586713 · Cited by 399
Self-citationEarly versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti
Severe, P., Jean Juste, M. A., Ambroise, A., Eliacin, L., Marchand, C., Apollon, S., Edwards, A., Bang, H., Nicotera, J., Godfrey, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910370 · Cited by 377
Ryom, L., Mocroft, A., Kirk, O., Worm, S. W., Kamara, D. A., Reiss, P., Ross, M., Fux, C. A., Morlat, P., Moranne, O., et al. (2013) · Journal of Infectious Diseases · doi:10.1093/infdis/jit043 · Cited by 301
Eaton, J. W., Menzies, N. A., Stover, J., Cambiano, V., Chindelevitch, L., Cori, A., Hontelez, J. A. C., Humair, S., Kerr, C. C., Klein, D. J., et al. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70172-4 · Cited by 241
The HIV-CAUSAL Collaboration* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00001 · Cited by 235
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2008) · The Journal of Infectious Diseases · doi:10.1086/529523 · Cited by 204
Self-citationBaker, J. V., Neuhaus, J., Duprez, D., Kuller, L. H., Tracy, R., Belloso, W. H., De Wit, S., Drummond, F., Lane, H. C., Ledergerber, B., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181f7f61a · Cited by 162
The SMART Study Group* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-5-200809020-00003 · Cited by 135
Self-citationBabiker, A. G., Emery, S., Fätkenheuer, G., Gordin, F. M., Grund, B., Lundgren, J. D., Neaton, J. D., Pett, S. L., Phillips, A. N., Touloumi, G., et al. (2012) · Clinical Trials · doi:10.1177/1740774512440342 · Cited by 120
Writing Committee for the CASCADE Collaboration* (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.401 · Cited by 111
Mocroft, A., Furrer, H., Miro, J. M., Reiss, P., Mussini, C., Kirk, O., Abgrall, S., Ayayi, S., Bartmeyer, B., Braun, D., et al. (2013) · doi:10.7892/boris.44212 · Cited by 110
The UK Collaborative HIV Cohort Study Steering Committee (2007) · AIDS · doi:10.1097/qad.0b013e32827038bf · Cited by 94
Zeng, M., Paiardini, M., Engram, J. C., Beilman, G. J., Chipman, J. G., Schacker, T. W., Silvestri, G., & Haase, A. T. (2012) · Blood · doi:10.1182/blood-2012-03-418624 · Cited by 77
Cardiovascular implications from untreated human immunodeficiency virus infection
Baker, J. V., & Lundgren, J. D. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq483 · Cited by 75
Lodi, S., Phillips, A. N., Logan, R. W., Olson, A. D., Costagliola, D. G., Abgrall, S., van Sighem, A., Reiss, P., Miró, J. M., Ferrer, E., et al. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00108-3 · Cited by 68
When to Start ART in Africa — An Urgent Research Priority
Cock, K. M. D., & El-Sadr, W. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1300458 · Cited by 66
The CD4 lymphocyte count and risk of clinical progression
Phillips, A. N., & Lundgren, J. D. (2006) · Current Opinion in HIV and AIDS · doi:10.1097/01.coh.0000194106.12816.b1 · Cited by 65
Phillips, E., Gutiérrez, S., Jahnke, N., Yip, B., Lima, V. D., Hogg, R. S., Harrigan, P. R., & Montaner, J. S. G. (2007) · AIDS · doi:10.1097/qad.0b013e3282170a9d · Cited by 48
When to start antiretroviral therapy: the need for an evidence base during early HIV infection
Lundgren, J. D., Babiker, A. G., Gordin, F. M., Borges, Á. H., & Neaton, J. D. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-148 · Cited by 47
Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials
Lifson, A. R., Belloso, W. H., Davey, R. T., Duprez, D. A., Gatell, J. M., Hoy, J., Krum, E. A., Nelson, R., Pedersen, C., Pérez, G. V., et al. (2010) · HIV Clinical Trials · doi:10.1310/hct1104-205 · Cited by 45
Self-citationRating evidence in treatment guidelines
Sabin, C. A., Cooper, D. A., Collins, S., & Schechter, M. (2013) · AIDS · doi:10.1097/qad.0b013e328360d546 · Cited by 44
Why START ? Reflections that led to the conduct of this large long‐term strategic HIV trial
The INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group (2015) · HIV Medicine · doi:10.1111/hiv.12227 · Cited by 39
Self-citationSoliman, E. Z., Sharma, S., Arastéh, K., Wohl, D. A., Achhra, A. C., Tambussi, G., O’Connor, J. L., Stein, J. H., Duprez, D., Neaton, J., et al. (2015) · HIV Medicine · doi:10.1111/hiv.12233 · Cited by 33
Maduna, P. H., Dolan, M., Kondlo, L., Mabuza, H., Dlamini, J. N., Polis, M., Mnisi, T., Orsega, S., Maja, P., Ledwaba, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121843 · Cited by 19
Lifson, A. R., Rhame, F. S., Belloso, W. H., Dragsted, U. B., El-Sadr, W. M., Gatell, J. M., Hoy, J., Krum, E. A., Nelson, R., Pedersen, C., et al. (2006) · HIV Clinical Trials · doi:10.1310/7mer-xfa7-1762-e2wr · Cited by 18
Perspectives, S. A. (2015) · Cited by 15
Baker, J., Engen, N. W., Hullsiek, K. H., Stephan, C., Jain, M. K., Munderi, P., Pett, S. L., Duprez, D. A., & International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group (2015) · HIV Medicine · doi:10.1111/hiv.12239 · Cited by 12
Rodger, A. J., Phillips, A. N., Speakman, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097340 · Cited by 12
Cited by
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Antiretroviral therapy for the prevention of HIV-1 transmission.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600693 · Cited by 1,700
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116846 · Cited by 1,231
Trickey, A., May, M. T., Vehreschild, J.-J., Obel, N., Gill, M. J., Crane, H. M., Boesecke, C., Patterson, S., Grabar, S., Cazanave, C., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30066-8 · Cited by 1,082
Metadata
- Authors
- The INSIGHT START Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-27
- Volume
- 373
- Issue
- 9
- Pages
- 795-807
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2238552371
- Cited by
- 2,798
- References
- 40
- FWCI
- 276.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.